Reviewer's report
Title:High efficacy in Helicobacter pylori retreatment: seven days with
furazolidone, levofloxacin and lansoprazole, in Sao Paulo, Brazil.
Version: 3Date:16 January 2009
Reviewer: Ala I Sharara
Reviewer's report:
The authors have addressed most of the concerns raised. However, the following
issues require additional clarifications and modifications. The authors have failed
to properly address one of the raised points (see below). Their response that
“The treatment schemes used in these patients already tested in our service
have shown fewer efficacies (4, 7 e 8). A Brazilian Helicobacter pylori sensibility
study showed a 13% furazolidone primary resistance (3). In another study (9),
the secondary furazolidone resistance was also low.” does NOT answer the
query on the eradication rate of patients who had previously failed one or more
furazolidone-containing regimen(s).
Major issues:
1. From table 2 (Table 3 in the first submission), it appears that 15 patients had
previously failed one (or more in the case of 2 patients) furazolidone-containing
regimen. It is therefore important to examine the eradication rate in such patients
compared to furazolidone-naïve patients. Moreover, 3 patients received “other”
regimens under the 3 or more prior regimen category. If any of those had
received furazolidone in the past, they need to be added to the analysis of the 15
listed above.
2. The discussion is very disjointed and needs to be rewritten as distinct
paragraphs addressing distinct points
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Not suitable for publication unless extensively edited
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
'I declare that I have no competing interests'
Reviewer's report
Title:High efficacy in Helicobacter pylori retreatment: seven days with
furazolidone, levofloxacin and lansoprazole, in Sao Paulo, Brazil.
Version: 3Date:16 January 2009
Reviewer: Ala I Sharara
Reviewer's report:
The authors have addressed most of the concerns raised. However, the following
issues require additional clarifications and modifications. The authors have failed
to properly address one of the raised points (see below). Their response that
“The treatment schemes used in these patients already tested in our service
have shown fewer efficacies (4, 7 e 8). A Brazilian Helicobacter pylori sensibility
study showed a 13% furazolidone primary resistance (3). In another study (9),
the secondary furazolidone resistance was also low.” does NOT answer the
query on the eradication rate of patients who had previously failed one or more
furazolidone-containing regimen(s).
Major issues:
1. From table 2 (Table 3 in the first submission), it appears that 15 patients had
previously failed one (or more in the case of 2 patients) furazolidone-containing
regimen. It is therefore important to examine the eradication rate in such patients
compared to furazolidone-naïve patients. Moreover, 3 patients received “other”
regimens under the 3 or more prior regimen category. If any of those had
received furazolidone in the past, they need to be added to the analysis of the 15
listed above.
2. The discussion is very disjointed and needs to be rewritten as distinct
paragraphs addressing distinct points
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Not suitable for publication unless extensively edited
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
'I declare that I have no competing interests'
Please review this paper.
user
Reviewer's report
Title:High efficacy in Helicobacter pylori retreatment: seven days with
furazolidone, levofloxacin and lansoprazole, in Sao Paulo, Brazil.
Version: 3Date:16 January 2009
Reviewer: Ala I Sharara
Reviewer's report:
The authors have addressed most of the concerns raised. However, the following
issues require additional clarifications and modifications. The authors have failed
to properly address one of the raised points (see below). Their response that
“The treatment schemes used in these patients already tested in our service
have shown fewer efficacies (4, 7 e 8). A Brazilian Helicobacter pylori sensibility
study showed a 13% furazolidone primary resistance (3). In another study (9),
the secondary furazolidone resistance was also low.” does NOT answer the
query on the eradication rate of patients who had previously failed one or more
furazolidone-containing regimen(s).
Major issues:
1. From table 2 (Table 3 in the first submission), it appears that 15 patients had
previously failed one (or more in the case of 2 patients) furazolidone-containing
regimen. It is therefore important to examine the eradication rate in such patients
compared to furazolidone-naïve patients. Moreover, 3 patients received “other”
regimens under the 3 or more prior regimen category. If any of those had
received furazolidone in the past, they need to be added to the analysis of the 15
listed above.
2. The discussion is very disjointed and needs to be rewritten as distinct
paragraphs addressing distinct points
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Not suitable for publication unless extensively edited
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
'I declare that I have no competing interests'
assistant